Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

AIDS

Volumn 25, Issue 3, 2011, Pages 357-365

  Smurzynski, Marlene ^a   Wu, Kunling ^a   Letendre, Scott ^b   Robertson, Kevin ^c   Bosch, Ronald J ^a   Clifford, David B ^d   Evans, Scott ^a   Collier, Ann C ^e   Taylor, Michael ^f   Ellis, Ronald ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral agents; central nervous system; HIV; HIV 1 RNA suppression; neurologic impairment

Indexed keywords

ABACAVIR; AMPRENAVIR; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR PLUS RITONAVIR; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VICRIVIROC; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COGNITION; DEMOGRAPHY; DRUG PENETRATION; DRUG USE; EXPERIENCE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COGNITION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RNA, VIRAL; VIRAL LOAD;

EID: 79551604850     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834171f8     Document Type: Article

References (29)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
2. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56:416-423.
3. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIVpositive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
4. Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 2004; 15:254-259.
5. Robertson KR, Smurzynski M, Parsons T, Wu K, Bosch R, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915-1921.
6. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009; 82:A99-A109.
7. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54:927-936.
8. Price RW, Deeks SG. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: clinical and pathogenetic implications for the central nervous system. J Neurovirol 2004; 10 (Suppl 1):44-51.
9. Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, et al. AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): rationale, design, and baseline characteristics. HIV Clinical Trials 2008; 9:268-281.
10. U.S. Army. Army Individual Test Battery: manual of directions and scoring. Washington, DC: War Department, Adjutant General's Office; 1994.
11. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAISR). New York: The Psychological Corporation; 1981.
12. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, et al. Clinical validation of the NeuroScreen. J Neurovirol 2005; 11:503-511.
13. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz, FL: Psychological Assessment Resources; 2004.
14. Taylor MJ, Heaton RK. Sensitivity and Specificity of WAIS-III/WMS-III Demographically Corrected Factor Scores in Neuropsychological Assessment. J Int Neuropsychol Soc 2001; 7:867-874.
15. Letendre S, Ellis RJ, Best B, Bhatt A, Marquie-Beck J, LeBlanc S, et al. Penetration and effectiveness of antiretroviral therapy in the central nervous system. Anti-inflammatory Anti-Allergy Agents Med Chem 2009; 8:169-183.
16. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
17. Letendre S, Capparelli E, Best B, Clifford D, Collier A, Gelman B, et al. Better antiretroviral penetration into the central nervous system is associated with lower CSF viral load. 13th Conference on Retroviruses and Opportunistic Infections, 2006, Denver, CO, Abstract 74.
18. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52:56-63.
19. Heaton RK. HIV-associated neurocognitive impairment (NCI) remains common in the era of combination antiretroviral therapy (CART): the CHARTER study. Neurology 2010 (in press).
20. Ellis R, Heaton R, Letendre S, Badiee J, Munoz-Moreno J, Vaida F, et al. Higher CD4 nadir is associated with reduced rates of HIV-associated neurocognitive disorders in the CHARTER study: potential implications for early treatment initiation. 17th Conference on Retroviruses and Opportunistic Infections, 2010, San Francisco, CA, Abstract 429.
21. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10:317-331.
22. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18 (Suppl 1):S19-S25.
23. Woods SP, Moran LM, Carey CL, Dawson MS, Iudicello JE, Gibson S, et al. Prospective memory in HIV infection: is 'remembering to remember' a unique predictor of self-reported medication management? Arch Clin Neuropsychol 2008; 23:257-270.
24. Marcotte TD, Lazzaretto D, Scott JC, Roberts E, Woods SP, Letendre S. Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. J Clin Exp Neuropsychol 2006; 28:13-28.
25. Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med 1994; 56:8-17.
26. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61:1699-1704.
27. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd, International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNSpenetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23:1893-1901.
28. Fox E, Bungay PM, Bacher J, McCully CL,Dedrick RL, Balis FM. Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 2002; 301:1003-1011.
29. Fenton KA. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis 2007; 45 (Suppl 4):S213-220.